New Nature Biotechnology research reported online July 10 describes in vivo cytosine base editing enhancements using virus-like particles combined with uracil DNA glycosylase inhibition. The study frames the work as improving editing efficiency—an ongoing challenge for base editors in living organisms. The investigators also paired platform-specific delivery with pharmacologic inhibition of DNA repair pathways to reduce unwanted byproducts and improve net editing performance. While the work is still preclinical in most base-editing contexts, it contributes to a key objective for gene-editing therapeutics: making editing efficient without compromising safety. Separately, another Nature Biotechnology report (also published online July 10) highlighted engineered ADAR systems enabling precision A-to-G DNA base editing, with an emphasis on minimizing “bystander” edits by design changes to the editing machinery. Together, the studies add momentum to the base-editing toolbox—especially for tissues where standard nuclease editing remains difficult—by targeting both delivery and editing fidelity simultaneously.